The National Medical Products Administration (NMPA) of China has approved Sinocelltech Group Ltd’s (SHA: 688520) finotonlimab, a programmed-death 1 (PD-1) monoclonal antibody (mAb), for use in combination with platinum-based chemotherapy as a first-line treatment for recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Sunshine Lake Pharma’s Antaitasvir Gains NMPA Approval for Hepatitis C
On the same day, Sunshine Lake Pharma Co., Ltd received NMPA approval for its antaitasvir, a non-structural protein 5A (NS5A) inhibitor. The Category 1 drug is now indicated for use in combination with yiqibuvir to treat chronic hepatitis C virus (HCV) infections of genotypes 1, 2, 3, and 6, including patients who have previously been treated with interferon, with or without compensatory cirrhosis.-Fineline Info & Tech
